Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETNB 89bio	$9.26 +1.1%	$11.07	$6.57 ▼ $22.93	$865.81M	1.04	1.25 million shs	87,783 shs
FLXN Flexion Therapeutics	$9.12	$9.20	$4.30 ▼ $13.66	$458.93M	1.53	1.18 million shs	N/A
GERN Geron	$3.80 +3.3%	$2.67	$1.64 ▼ $4.05	$2.08B	0.62	11.17 million shs	1.99 million shs
TXMD TherapeuticsMD	$1.96 +3.7%	$2.27	$1.86 ▼ $4.73	$22.60M	1.03	21,481 shs	2,197 shs
VRNA Verona Pharma	$16.27 -0.8%	$16.53	$11.83 ▼ $23.81	$1.31B	0.4	493,641 shs	152,543 shs

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETNB 89bio	-2.24%	-13.09%	-27.30%	-17.40%	-46.34%
FLXN Flexion Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
GERN Geron	+2.79%	+6.98%	+15.91%	+95.74%	+76.92%
TXMD TherapeuticsMD	-0.53%	-10.43%	-17.83%	-16.74%	-48.08%
VRNA Verona Pharma	+1.23%	+0.80%	+5.60%	-4.54%	-25.45%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETNB 89bio	1.3278 of 5 stars	4.3	1.0	0.0	0.0	0.6	1.7	0.0
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GERN Geron	3.3279 of 5 stars	3.5	3.0	0.0	1.3	2.0	1.7	0.6
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	1.109 of 5 stars	3.5	0.0	0.0	0.0	2.0	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETNB 89bio	2.67	Moderate Buy	$28.83	211.38% Upside
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A
GERN Geron	3.00	Buy	$5.33	40.35% Upside
TXMD TherapeuticsMD	2.00	Hold	N/A	N/A
VRNA Verona Pharma	3.00	Buy	$33.60	106.52% Upside

Current Analyst Ratings

Latest GERN, ETNB, FLXN, VRNA, and TXMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2024	VRNA Verona Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$31.00 ➝ $36.00
4/11/2024	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
4/10/2024	GERN Geron	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$6.00
4/5/2024	ETNB 89bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$29.00
3/27/2024	ETNB 89bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
3/15/2024	GERN Geron	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$6.00
3/15/2024	GERN Geron	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
3/15/2024	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
3/13/2024	ETNB 89bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
3/6/2024	ETNB 89bio	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$29.00 ➝ $37.00
3/5/2024	ETNB 89bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETNB 89bio	N/A	N/A	N/A	N/A	$5.75 per share	N/A
FLXN Flexion Therapeutics	$85.55M	5.36	N/A	N/A	($0.34) per share	-26.82
GERN Geron	$240K	8,658.78	N/A	N/A	$0.46 per share	8.26
TXMD TherapeuticsMD	$1.30M	17.38	N/A	N/A	$2.77 per share	0.71
VRNA Verona Pharma	$460K	2,858.57	N/A	N/A	$3.10 per share	5.25

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETNB 89bio	-$142.19M	-$2.01	N/A	N/A	N/A	N/A	-31.01%	-27.84%	5/2/2024 (Estimated)
FLXN Flexion Therapeutics	-$113.71M	-$2.01	N/A	N/A	N/A	-100.32%	N/A	-44.26%	N/A
GERN Geron	-$184.13M	-$0.33	N/A	N/A	N/A	-77,691.14%	-63.33%	-44.71%	5/9/2024 (Estimated)
TXMD TherapeuticsMD	-$10.28M	N/A	0.00	∞	N/A	N/A	-25.54%	-14.87%	5/20/2024 (Estimated)
VRNA Verona Pharma	-$54.37M	-$0.69	N/A	N/A	N/A	N/A	-20.47%	-17.72%	5/14/2024 (Estimated)

Latest GERN, ETNB, FLXN, VRNA, and TXMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/29/2024	Q4 2023	ETNB 89bio	-$0.49	-$0.50	-$0.01	-$0.50	N/A	N/A
2/29/2024	Q4 2023	VRNA Verona Pharma	-$0.23	-$0.16	+$0.07	-$0.16	N/A	N/A
2/28/2024	Q4 23	GERN Geron	-$0.10	-$0.09	+$0.01	-$0.09	$0.06 million	$0.02 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETNB 89bio	N/A	N/A	N/A	N/A	N/A
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETNB 89bio	0.05	20.04	20.04
FLXN Flexion Therapeutics	N/A	4.38	4.05
GERN Geron	0.14	3.16	3.16
TXMD TherapeuticsMD	N/A	1.72	1.72
VRNA Verona Pharma	0.20	33.33	33.33

Ownership

Institutional Ownership

Company	Institutional Ownership
ETNB 89bio	N/A
FLXN Flexion Therapeutics	90.01%
GERN Geron	73.71%
TXMD TherapeuticsMD	30.74%
VRNA Verona Pharma	85.88%

Insider Ownership

Company	Insider Ownership
ETNB 89bio	4.40%
FLXN Flexion Therapeutics	9.13%
GERN Geron	3.10%
TXMD TherapeuticsMD	1.20%
VRNA Verona Pharma	4.80%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ETNB 89bio	70	93.50 million	89.39 million	Optionable
FLXN Flexion Therapeutics	257	50.32 million	45.73 million	Optionable
GERN Geron	141	546.87 million	529.92 million	Optionable
TXMD TherapeuticsMD	1	11.53 million	11.39 million	Optionable
VRNA Verona Pharma	79	80.82 million	76.94 million	Optionable

GERN, ETNB, FLXN, VRNA, and TXMD Headlines

Source	Headline
	Verona Pharma (NASDAQ:VRNA) Price Target Increased to $36.00 by Analysts at Piper Sandler americanbankingnews.com - April 17 at 3:36 AM
	Verona Pharma (NASDAQ:VRNA) Trading 3.7% Higher After Analyst Upgrade americanbankingnews.com - April 17 at 1:08 AM
	Verona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst Upgrade marketbeat.com - April 16 at 10:36 AM
	Verona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper Sandler marketbeat.com - April 16 at 8:33 AM
	Verona Pharma (NASDAQ:VRNA) Shares Up 4.9% marketbeat.com - April 4 at 3:08 PM
	American Century Companies Inc. Purchases Shares of 280,126 Verona Pharma plc (NASDAQ:VRNA) marketbeat.com - March 28 at 4:07 AM
	Wellington Management Group LLP Acquires 164,268 Shares of Verona Pharma plc (NASDAQ:VRNA) marketbeat.com - March 19 at 4:54 AM
	VRNA Apr 2024 17.500 call finance.yahoo.com - March 16 at 8:32 AM
	VRNA Apr 2024 15.000 call finance.yahoo.com - March 16 at 3:31 AM
	Andrew Fisher Joins Verona Pharma as General Counsel globenewswire.com - March 4 at 2:00 AM
	Buy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipeline markets.businessinsider.com - March 1 at 1:10 PM
	Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 1 at 1:10 PM
	3 Healthcare Stocks That Have Outperformed Nvidia Since 2022 fool.com - March 1 at 8:45 AM
	Verona Pharma plc 2023 Q4 - Results - Earnings Call Presentation seekingalpha.com - February 29 at 11:18 AM
	Verona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update finanznachrichten.de - February 29 at 10:48 AM
	Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results finance.yahoo.com - February 29 at 10:48 AM
	Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update globenewswire.com - February 29 at 2:00 AM
	Verona Pharma earnings preview: what to expect markets.businessinsider.com - February 28 at 1:35 PM
	When Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit? finance.yahoo.com - February 25 at 12:52 PM
	Verona Pharma PLC ADR wsj.com - February 25 at 7:52 AM
	VRNA Mar 2024 15.000 put finance.yahoo.com - February 17 at 7:46 PM
	VRNA Jun 2024 30.000 call finance.yahoo.com - February 17 at 2:46 PM
	Verona Pharma: A Few Points From The Bull And Bear Case seekingalpha.com - February 15 at 5:55 PM
	Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update finance.yahoo.com - February 15 at 10:20 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
March 20, 2024 6:10 AM
View Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

All Headlines

Company Descriptions

89bio

NASDAQ:ETNB

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Flexion Therapeutics

NASDAQ:FLXN

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Geron

NASDAQ:GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

TherapeuticsMD

NASDAQ:TXMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Verona Pharma

NASDAQ:VRNA

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial